Rezultati - Popat, Rakesh
- Showing 1 - 20 results of 26
- Go to Next Page
-
1
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case seri... od Popat, Rakesh, Warcel, Dana, O’Nions, Jenny, Cowley, Anna, Smith, Sasha, Tucker, William R, Yong, Kwee, Esposti, Simona Degli
Izdano 2020Text -
2
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma od Prawitz, Thibaud, Popat, Rakesh, Suvannasankha, Attaya, Sarri, Grammati, Hughes, Rachel, Wang, Feng, Hogea, Cosmina, Ferrante, Shannon Allen, Gorsh, Boris, Willson, Jenny, Kapetanakis, Venediktos
Izdano 2021Text -
3
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response od Latifoltojar, Arash, Hall‐Craggs, Margaret, Rabin, Neil, Popat, Rakesh, Bainbridge, Alan, Dikaios, Nikolaos, Sokolska, Magdalena, Rismani, Ali, D'Sa, Shirley, Punwani, Shonit, Yong, Kwee
Izdano 2016Text -
4
A Phase I trial of talazoparib in patients with advanced hematologic malignancies od Gopal, Ajay K, Popat, Rakesh, Mattison, Ryan J, Menne, Tobias, Bloor, Adrian, Gaymes, Terry, Khwaja, Asim, Juckett, Mark, Chen, Ying, Cotter, Matthew J, Mufti, Ghulam J
Izdano 2021Text -
5
Deferred autologous stem cell transplantation in systemic AL amyloidosis od Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh
Izdano 2018Text -
6
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study od Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.
Izdano 2019Text -
7
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induc... od Latifoltojar, Arash, Hall-Craggs, Margaret, Bainbridge, Alan, Rabin, Neil, Popat, Rakesh, Rismani, Ali, D’Sa, Shirley, Dikaios, Nikolaos, Sokolska, Magdalena, Antonelli, Michela, Ourselin, Sebastien, Yong, Kwee, Taylor, Stuart A., Halligan, Steve, Punwani, Shonit
Izdano 2017Text -
8
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiv... od Cook, Gordon, John Ashcroft, A, Pratt, Guy, Popat, Rakesh, Ramasamy, Karthik, Kaiser, Martin, Jenner, Matthew, Henshaw, Sarah, Hall, Rachel, Sive, Jonathan, Stern, Simon, Streetly, Matthew, Bygrave, Ceri, Soutar, Richard, Rabin, Neil, Jackson, Graham H
Izdano 2020Text -
9
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma od Lecat, Catherine S. Y., Taube, Jessica B., Wilson, William, Carmichael, Jonathan, Parrish, Christopher, Wallis, Gabriel, Kyriakou, Charalampia, Lee, Lydia, Mahmood, Shameem, Papanikolaou, Xenofon, Rabin, Neil K., Sive, Jonathan, Wechalekar, Ashutosh D., Yong, Kwee, Cook, Gordon, Popat, Rakesh
Izdano 2021Text -
10
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial od Camilleri, Marquita, Sive, Jonathan, Wilson, William, Pang, Gavin, Jenner, Richard, Phillips, Elizabeth, Popat, Rakesh, Ramasamy, Karthik, Bygrave, Ceri, Dadaga, Tushhar, Streetly, Matthew, Cavenagh, James, Chapman, Mike, Barrington, Sally, Pike, Lucy, Owen, Roger, Clifton‐Hadley, Laura, Yong, Kwee
Izdano 2020Text -
11
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia od Salamero, Olga, Montesinos, Pau, Willekens, Christophe, Pérez-Simón, José Antonio, Pigneux, Arnaud, Récher, Christian, Popat, Rakesh, Carpio, Cecilia, Molinero, César, Mascaró, Cristina, Vila, Joaquim, Arévalo, M. Isabel, Maes, Tamara, Buesa, Carlos, Bosch, Francesc, Somervaille, Tim C. P.
Izdano 2020Text -
12
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study od Camilleri, Marquita, Bekris, Georgios, Sidhu, Govundeep, Buck, Caroline, Elsden, Esma, McCourt, Orla, Horder, Jackie, Newrick, Fiona, Lecat, Catherine, Sive, Jonathan, Papanikolaou, Xenofon, Popat, Rakesh, Lee, Lydia, Xu, Ke, Kyriakou, Charalampia, Rabin, Neil, Yong, Kwee, Fisher, Abigail
Izdano 2022Text -
13
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy od Chan, Wei Yee, Sanchez, Emilie, Chavda, Selina J., Lecat, Catherine S. Y., Ainley, Louise, Xu, Ke, Wisniowski, Brendan, Mahmood, Shameem, Papanikolaou, Xenofon, Kyriakou, Charalampia, Sive, Jonathan, Wechalekar, Ashutosh, Popat, Rakesh, Rabin, Neil, Lee, Lydia, Nastouli, Eleni, Yong, Kwee L.
Izdano 2021Text -
14
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modifie... od Koutoukidis, Dimitrios A., Land, Joanne, Hackshaw, Allan, Heinrich, Malgorzata, McCourt, Orla, Beeken, Rebecca J., Philpott, Stephanie, DeSilva, Dunnya, Rismani, Ali, Rabin, Neil, Popat, Rakesh, Kyriakou, Charalampia, Papanikolaou, Xenofon, Mehta, Atul, Paton, Bruce, Fisher, Abigail, Yong, Kwee L.
Izdano 2020Text -
15
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma od Ramasamy, Karthik, Nooka, Ajay, Quach, Hang, Htut, Myo, Popat, Rakesh, Liedtke, Michaela, Tuchman, Sascha A., Laubach, Jacob, Gasparetto, Cristina, Chanan-Khan, Asher, Hertzberg, Mark, deMario, Mark, Nueesch, Eveline, Chesne, Evelyne, Franjkovic, Izolda, Lechner, Katharina, Kornacker, Martin, Cho, Hearn Jay
Izdano 2021Text -
16
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma od Morris, Treen Carson Michael, Drake, Mary B., Kettle, Paul J., McGuigan, Tracey, Leahy, Maeve, O’Dwyer, Michael, Enright, Helen, O’Shea, Tanya, Popat, Rakesh, Oakervee, Heather E., Yong, Kwee, Cavenagh, Jamie D., Cairns, David A., Alvarez-Iglesias, Alberto, Cook, Gordon
Izdano 2021Text -
17
Targeting B-Cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma: A Dose-Escalation and Expansion Phase 1 Trial (BMA117159) od Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Anderson, Larry D., Sutherland, Heather J., Yong, Kwee, Hoos, Axel, Gorczyca, Michele M., Lahiri, Soumi, He, Zangdong, Austin, Daren J., Opalinska, Joanna B., Cohen, Adam D.
Izdano 2018Text -
18
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study od Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn
Izdano 2020Text -
19
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study od Farooq, Asim V., Degli Esposti, Simona, Popat, Rakesh, Thulasi, Praneetha, Lonial, Sagar, Nooka, Ajay K., Jakubowiak, Andrzej, Sborov, Douglas, Zaugg, Brian E., Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Opalinska, Joanna, Baron, January, Piontek, Trisha, Byrne, Julie, Gupta, Ira, Colby, Kathryn
Izdano 2020Text -
20
European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma od Bruno, Benedetto, Wäsch, Ralph, Engelhardt, Monika, Gay, Francesca, Giaccone, Luisa, D’Agostino, Mattia, Rodríguez-Lobato, Luis-Gerardo, Danhof, Sophia, Gagelmann, Nico, Kröger, Nicolaus, Popat, Rakesh, van de Donk, Niels W C J, Terpos, Evangelos, Dimopoulos, Meletios A, Sonneveld, Pieter, Einsele, Hermann, Boccadoro, Mario
Izdano 2021Text